Castle Biosciences, Inc. - Laporan Laba Rugi (TTM)

Castle Biosciences, Inc.
US ˙ NasdaqGM ˙ US14843C1053

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Castle Biosciences, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 63 63 68 78 86 94 98 110 124 137 152 168 192 220 251 288 312 332 347 346
Change (%) -0.53 8.61 14.76 10.58 8.96 4.29 12.31 12.28 10.75 11.08 10.05 14.61 14.47 14.08 14.70 8.45 6.47 4.52 -0.23
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 9 10 10 12 14 16 19 23 27 32 36 40 42 45 49 52 56 60 63 66
Change (%) 7.34 6.58 15.03 17.06 13.84 18.43 21.29 19.18 18.18 13.24 9.30 6.21 6.90 8.25 7.11 8.23 6.66 4.13 4.96
% of Revenue 14.33 15.46 15.17 15.20 16.10 16.82 19.10 20.62 21.89 23.36 23.81 23.65 21.92 20.47 19.42 18.14 18.10 18.13 18.06 19.00
Gross Operating Profit 54 53 58 66 72 78 79 87 97 105 116 128 150 175 202 235 255 272 284 280
Change (%) -1.85 8.98 14.71 9.41 8.03 1.43 10.19 10.49 8.67 10.42 10.28 17.22 16.59 15.57 16.53 8.49 6.43 4.61 -1.38
% of Revenue 85.67 84.54 84.83 84.80 83.90 83.18 80.90 79.38 78.11 76.64 76.19 76.35 78.08 79.53 80.58 81.86 81.90 81.87 81.94 81.00
SG&A 43 48 55 66 77 87 99 114 130 143 159 168 174 180 182 188 194 200 210 217
Change (%) 11.87 14.72 18.89 16.59 13.33 14.17 15.11 13.81 10.23 11.40 5.58 3.73 3.25 0.96 3.52 3.12 3.03 5.06 3.32
% of Revenue 68.31 76.83 81.15 84.07 88.64 92.19 100.92 103.44 104.85 104.35 104.66 100.41 90.88 81.97 72.54 65.47 62.26 60.24 60.55 62.71
R&D 12 13 16 20 25 30 34 40 43 45 49 50 52 54 53 54 53 52 51 49
Change (%) 12.02 22.59 25.16 21.84 19.63 16.37 14.88 8.60 4.33 8.09 2.85 4.04 3.24 -1.09 1.56 -1.11 -2.29 -2.35 -2.65
% of Revenue 18.79 21.16 23.88 26.05 28.70 31.51 35.16 35.96 34.78 32.77 31.88 29.80 27.05 24.40 21.15 18.73 17.08 15.67 14.64 14.29
OpEx 64 71 82 98 116 134 156 182 207 228 253 267 277 288 293 303 313 323 361 369
Change (%) 11.26 15.08 19.96 18.40 15.49 16.18 16.63 13.82 10.27 10.85 5.46 4.02 3.72 1.70 3.65 3.15 3.35 11.59 2.34
% of Revenue 101.42 113.45 120.20 125.65 134.54 142.60 158.85 164.97 167.22 166.51 166.16 159.22 144.50 130.93 116.72 105.48 100.33 97.39 103.97 106.66
Operating Income -1 -8 -14 -20 -30 -40 -58 -72 -83 -91 -101 -99 -85 -68 -42 -16 -1 9 -14 -23
Change (%) 839.13 63.15 45.71 48.91 34.39 44.09 23.98 16.18 9.57 10.50 -1.49 -13.87 -20.45 -38.32 -62.42 -93.41 -935.26 -259.02 67.19
% of Revenue -1.42 -13.45 -20.20 -25.65 -34.54 -42.60 -58.85 -64.97 -67.22 -66.51 -66.16 -59.22 -44.50 -30.93 -16.72 -5.48 -0.33 2.61 -3.97 -6.66
Interest Expense -3 -3 -2 -1 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -1 -1 -0
Change (%) -12.35 -29.01 -41.12 -64.12 -99.75 300.00 100.00 75.00 21.43 5.88 -5.56 -23.53 -15.38 90.91 1,271.43 69.10 18.48 0.52 -42.93
% of Revenue -4.77 -4.20 -2.75 -1.41 -0.46 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.10 -0.16 -0.17 -0.17 -0.10
Net Income -3 -10 -15 -23 -30 -31 -52 -44 -53 -67 -72 -89 -76 -57 -31 -3 6 18 -5 -9
Change (%) 207.90 47.16 49.00 31.94 5.18 65.01 -13.83 19.01 26.80 6.82 23.88 -15.02 -23.89 -46.41 -89.94 -296.03 200.33 -127.78 86.74
% of Revenue -5.30 -16.42 -22.24 -28.88 -34.46 -33.26 -52.62 -40.37 -42.79 -48.99 -47.11 -53.04 -39.32 -26.15 -12.28 -1.08 1.95 5.49 -1.46 -2.73

Source: Capital IQ

Other Listings
DE:086
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista